Hyperbare zuurstoftherapie na bestraling geeft significant betere kwaliteit van leven bij patienten die bestraald zijn voor kanker in mond- en neusgebied. Artikel update 2 februari 2012
9 oktober 2009: Bron: Tijdschrift Radiation Oncology
Hyperbare zuurstoftherapie na bestraling geeft significant betere kwaliteit van leven bij patienten die bestraald zijn voor kanker in mond- en neusgebied. Dit concluderen Nederlandse onderzoekers uit een kleinschalige maar wel gerandomiseerde studie bij 19 patienten met tong- en neuskanker. Op alle onderzoekspunten voor kwaliteit van leven, zoals beter slikken, minder droge mond door verminderde speeksel aanmaak en ook pijn in de mond, scoorden de patienten die de hyperbare zuurstoftherapie kregen significant beter dan de patienten die geen hyperbare zuurstoftherapie kregen.
Early Hyperbaric Oxygen Therapy for Reducing Radiotherapy Side Effects: Early Results of a Randomized Trial in Oropharyngeal and Nasopharyngeal Cancer
Received 24 July 2008; received in revised form 24 November 2008; accepted 27 November 2008. published online 21 April 2009.
Purpose
Comparison of quality of life (QoL) and side effects in a randomized trial for early hyperbaric oxygen therapy (HBOT) after radiotherapy (RT).
Methods and Materials
From 2006, 19 patients with tumor originating from the tonsillar fossa and/or soft palate (15), base of tongue (1), and nasopharynx (3) were randomized to receive HBOT or not. HBOT consisted of 30 sessions at 2.5 ATA (15 msw) with oxygen breathing for 90 min daily, 5 days per week, applied shortly after the RT treatment was completed. As of 2005, all patients received validated questionnaires (i.e., the European Organization for Research and Treatment of Cancer [EORTC] QLQ-C30, EORTC QLQ Head and Neck Cancer Module (H&N35), Performance Status Scale): before treatment; at the start of RT treatment; after 46 Gy; at the end of RT treatment; and 2, 4, and 6 weeks and 3, 6, 12, and 18 months after follow-up.
Results
On all QoL items, better scores were obtained in patients treated with hyperbaric oxygen. The difference between HBOT vs. non-HBOT was significant for all parameters: EORTC H&N35 Swallowing (p = 0.011), EORTC H&N35 Dry Mouth (p = 0.009), EORTC H&N35, Sticky Saliva (p = 0.01), PSS Eating in Public (p = 0.027), and Pain in Mouth (visual analogue scale; p < 0.0001).
Conclusions
Patients randomized for receiving hyperbaric oxygen after the RT had better QoL scores for swallowing, sticky saliva, xerostomia, and pain in mouth.
